Research programme: adenovirus-based cancer therapy - BTG

Drug Profile

Research programme: adenovirus-based cancer therapy - BTG

Latest Information Update: 03 May 2007

Price : $50

At a glance

  • Originator BTG
  • Class Oncolytic viruses
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 May 2007 Discovery/lead optimisation is ongoing
  • 24 Oct 2002 A preclinical study has been added to the Cancer pharmacodynamics section
  • 16 May 2002 Preclinical trials in Cancer in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top